Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD.
作者信息
Hiremath Swapnil, McGuinty Michaeline, Argyropoulos Christos, Brimble K Scott, Brown Pierre Antoine, Chagla Zain, Cooper Rebecca, Hoar Stephanie, Juurlink David, Treleaven Darin, Walsh Michael, Yeung Angie, Blake Peter
机构信息
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Canada.
Division of Infectious Disease, Department of Medicine, University of Ottawa, Ottawa, Canada.
出版信息
Clin J Am Soc Nephrol. 2022 Aug;17(8):1247-1250. doi: 10.2215/CJN.05270522. Epub 2022 Jun 9.
Abstract
摘要
相似文献
1
Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD.
Clin J Am Soc Nephrol. 2022 Aug;17(8):1247-1250. doi: 10.2215/CJN.05270522. Epub 2022 Jun 9.
2
Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0122922. doi: 10.1128/aac.01229-22. Epub 2022 Oct 26.
3
Nirmatrelvir and Ritonavir Combination in COVID-19 Patients With Advanced Chronic Kidney Disease.
Clin Infect Dis. 2024 Sep 26;79(3):798-800. doi: 10.1093/cid/ciad785.
4
Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
Pediatr Nephrol. 2023 Apr;38(4):1387-1388. doi: 10.1007/s00467-022-05712-0. Epub 2022 Aug 19.
5
Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
Front Immunol. 2023 Apr 4;14:1150341. doi: 10.3389/fimmu.2023.1150341. eCollection 2023.
6
Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
BMC Nephrol. 2023 Apr 15;24(1):99. doi: 10.1186/s12882-023-03154-w.
7
Nirmatrelvir Plus Ritonavir: First Approval.
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
8
Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.
Clin Pharmacol Ther. 2022 Oct;112(4):803-807. doi: 10.1002/cpt.2687. Epub 2022 Jul 4.
9
Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
Obstet Gynecol. 2022 Sep 1;140(3):447-449. doi: 10.1097/AOG.0000000000004900. Epub 2022 Jun 28.
10
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
引用本文的文献
1
Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19.
Am J Kidney Dis. 2025 Apr 7. doi: 10.1053/j.ajkd.2025.02.603.
2
The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study.
Open Forum Infect Dis. 2024 Dec 31;12(1):ofae756. doi: 10.1093/ofid/ofae756. eCollection 2025 Jan.
3
Kidney failure-related excess mortality during the first three years of the COVID-19 pandemic in the United States: a nation-wide, population-based analysis.
BMC Public Health. 2025 Jan 17;25(1):210. doi: 10.1186/s12889-025-21422-2.
4
IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19.
Pediatr Nephrol. 2025 May;40(5):1795-1815. doi: 10.1007/s00467-024-06565-5. Epub 2024 Dec 29.
5
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19.
BMC Infect Dis. 2024 Dec 18;24(1):1425. doi: 10.1186/s12879-024-10291-6.
6
Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients.
Infect Drug Resist. 2024 Sep 17;17:4055-4065. doi: 10.2147/IDR.S471918. eCollection 2024.
7
The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
Ren Fail. 2024 Dec;46(2):2385724. doi: 10.1080/0886022X.2024.2385724. Epub 2024 Sep 16.
8
COVID-19 therapeutics.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0011923. doi: 10.1128/cmr.00119-23. Epub 2024 May 21.
9
Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
EClinicalMedicine. 2024 May 3;72:102620. doi: 10.1016/j.eclinm.2024.102620. eCollection 2024 Jun.
10
Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.
Eur J Clin Pharmacol. 2024 Aug;80(8):1219-1227. doi: 10.1007/s00228-024-03691-9. Epub 2024 May 1.
Zotero 插件